OS Therapies (OSTX) Stock Price, News & Analysis

Company Overview

OS Therapies (NYSE: OSTX) is a clinical-stage biotechnology company dedicated to developing innovative cancer immunotherapies through the localized delivery of therapeutic genes. The company’s proprietary platform combines electroporation technology with plasmid DNA constructs to stimulate anti-tumor immune responses directly within solid tumors. Headquartered in San Diego, California, OS Therapies focuses on creating treatments that harness the body’s own immune system to target and eliminate malignant cells.

The cornerstone of OS Therapies’ pipeline is its ImmunoPulse® IL-12 program, which delivers interleukin-12 encoding plasmids into tumors via a minimally invasive electroporation device. This approach has been evaluated across multiple tumor types, including non-small cell lung cancer, melanoma, pancreatic cancer, and head and neck cancers. Preclinical studies and early-stage clinical trials have demonstrated encouraging signs of tumor regression, immune cell activation, and manageable safety profiles, supporting further development in combination with established immuno-oncology agents.

Founded in 2008, OS Therapies has built a strong foundation in gene therapy and electroporation expertise. Over the years, the company has collaborated with leading academic institutions and clinical research centers to refine its delivery technology and expand its therapeutic applications. In addition to its U.S. operations, OS Therapies is advancing partnerships in Europe and Asia to facilitate multi-regional trials and regulatory submissions, reflecting its commitment to bringing novel treatments to patients worldwide.

OS Therapies is led by a management team and board of directors with extensive experience in biotech innovation, clinical development, and regulatory strategy. The company continues to invest in research and development to broaden its pipeline, enhance product candidates, and explore new indications. Through its focus on precision delivery and immunomodulation, OS Therapies aims to establish a new standard of care for patients with hard-to-treat solid tumors.

Key Stats

• Today's Range: $1.55 to $1.75
• 50-Day Range: $1.45 to $2.34
• 52-Week Range: $1.12 to $7.00
• Volume: 492,116 shs
• Average Volume: 492,354 shs
• Market Capitalization: $45.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Buy

OS Therapies Stock Analysis - MarketRank™

OS Therapies scored higher than 56% of companies evaluated by MarketBeat, and ranked 494th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

OS Therapies has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

OS Therapies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OS Therapies are expected to grow in the coming year, from ($0.64) to ($0.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OS Therapies is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OS Therapies is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OSTX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OS Therapies does not currently pay a dividend.

Dividend Growth

OS Therapies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for OSTX.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.17

News Sentiment

OS Therapies has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for OS Therapies this week, compared to 2 articles on an average week.

Search Interest

16 people have searched for OSTX on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.

MarketBeat Follows

6 people have added OS Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, OS Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $231,516.00 in company stock.

Percentage Held by Insiders

13.80% of the stock of OS Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.

OSTX Stock Analysis - Frequently Asked Questions

How have OSTX shares performed this year?

OS Therapies' stock was trading at $4.28 at the start of the year. Since then, OSTX stock has decreased by 62.1% and is now trading at $1.62.

When did OS Therapies IPO?

OS Therapies (OSTX) raised $8 million in an initial public offering on Thursday, August 1st 2024. The company issued 2,000,000 shares at a price of $4.00 per share. Brookline Capital Markets (Division of Arcadia Securities LLC) acted as the underwriter for the IPO.

How do I buy shares of OS Therapies?

Shares of OSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OS Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OS Therapies investors own include AST SpaceMobile (ASTS), Energy Transfer (ET), Black Stone Minerals (BSM), Kinder Morgan (KMI), Main Street Capital (MAIN), Atlas Energy Solutions (AESI) and Chevron (CVX).

Company Calendar

• Today: 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:OSTX
• Previous Symbol: NYSE:OSTX
• CIK: 1795091
• Web: N/A
• Phone: (410) 297-7793
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OS Therapies: $18.00
• High Price Target: $20.00
• Low Price Target: $15.00
• Potential Upside/Downside: +1,011.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -569.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.76
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 28,098,000
• Free Float: N/A
• Market Cap: $45.52 million
• Optionable: N/A
• Beta: N/A